| Literature DB >> 33289456 |
Sahabjada Siddiqui1, Shivbrat Upadhyay1, Rumana Ahmad2, Anamika Gupta2, Aditi Srivastava2, Anchal Trivedi2, Ishrat Husain2, Bilal Ahmad3, Maqusood Ahamed4, Mohsin Ali Khan5.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel etiological agent of coronavirus disease 2019 (COVID-19). Nigella sativa, commonly known as black seed or black cumin, has been a historical and traditional plant since thousands of years. Based on their therapeutic efficacy, the chief components of terpenoids and flavonoids were selected from N. sativa seeds and seed oil. This study was designed to check the antiviral efficacy of N. sativa main phytoconstituents against five potential targets of SARS-CoV-2 using in silico structure-based virtual screening approach. Out of twenty five phytocomponents, ten components showed best binding affinity against two viral proteins viz. N-terminal RNA binding domain (NRBD; PDB ID: 6M3M) of nucleocapsid protein and papain-like protease (PL-PRO; PDB ID: 6W9C) of SARS-CoV-2 using AutoDock 4.2.6, AutoDock Vina and iGEMDOCK. PASS analyses of all ten phytocomponents using Lipinski's Rule of five showed promising results. Further, druglikeness and toxicity assessment using OSIRIS Data Warrior v5.2.1 software exhibited the feasibility of phytocomponents as drug candidates with no predicted toxicity. Molecular dynamics simulation study of NRBD of SARS-CoV-2 nucleocapsid protein-alpha-spinasterol complex and PL-PRO-cycloeucalenol complex displayed strong stability at 300 K. Both these complexes exhibited constant root mean square deviation (RMSDs) of protein side chains and Cα atoms throughout the simulation run time. Interestingly, PL-PRO and NRBD are key proteins in viral replication, host cell immune evasion and viral assembly. Thus, NRBD and PL-PRO have the potential to serve as therapeutic targets for N. sativa phytoconstituents in drug discovery process against COVID-19.Entities:
Keywords: Nigella sativa; SARS-CoV-2; molecular chemoinformatics; nucleocapsid protein; papain-like protease; phytocomponents
Mesh:
Substances:
Year: 2020 PMID: 33289456 PMCID: PMC7738213 DOI: 10.1080/07391102.2020.1852117
Source DB: PubMed Journal: J Biomol Struct Dyn ISSN: 0739-1102
List of ten bioactive components from N. sativa, standard drugs hydroxychloroquine and ivermectin and their respective binding to nucleocapsid protein (PDB ID: 6M3M) and papain-like protease (PL-PRO, PDB ID: 6W9C) of SARS-CoV-2.
| S. No. | Ligands | PDB: ID (SARS-CoV-2) | MF and MW of phyto-components | Molecular Structure | Pub | Chemical Class of Ligands | Source |
|---|---|---|---|---|---|---|---|
| 1. | 24-methylene- cycloartanol | 6M3M | MF: C31H52O | 94204 | Pentacyclic triterpenoid | Seed oil | |
| 2. | Alpha-spinasterol | 6M3M | MF: C29H48O | 5281331 | Steroid | Seed/seed oil | |
| 3. | Beta-amyrin | 6W9C | MF: C30H50O | 73145 | Pentacyclic triterpenoid | Seed oil | |
| 4. | Beta-sitosterol | 6M3M | MF: C29H50O | 222284 | Phytosterol | Seed oil | |
| 5. | Campesterol | 6M3M | MF: C28H48O | 173183 | Phytosterols | Seed/seed oil | |
| 6. | Citrostadienol | 6M3M | MF: C30H50O | 9548595 | Sterol | Seed oil | |
| 7. | Cycloartenol | 6W9C | MF: C30H50O | 92110 | Pentacyclic triterpenoid | Seed oil | |
| 8. | Cycloeucalenol | 6M3M | MF: C30H50O | 101690 | Pentacyclic triterpenoid | Seed oil | |
| 9. | Taraxerol | 6M3M | MF: C30H50O | 92097 | Pentacyclic triterpenoid | Seed oil | |
| 10. | Tirucallol | 6W9C | MF: C30H50O | 101257 | Tetracyclic triterpene | Seed oil | |
| 11. | Hydroxy- chloroquine | 6M3M | MF: C18H26ClN3O | 3652 | 4-aminoquinoline | Chemotherapeutic agent | |
| 12. | Ivermectin | 6M3M | MF: C48H74O14 MW: 875.1 | 6321424 | Macrocyclic lactone (Standard drug) | Derived from |
Best docking poses of active components of N. sativa with N-terminal RNA binding domain (NRBD) of SARS-CoV-2 nucleocapsid protein (PDB ID: 6M3M) in comparison to standard drugs hydroxychloroquine and ivermectin. In AutoDock v4.2.6 analyses, ligand is represented as CPK model colored by- H = White, C = Grey, N = Blue, O = Red, S = Yellow, Pink = other elements. In AutoDock Vina, ligand is represented by 2-D line model, whereas in iGEMDOCK v2.1 analyses, ligand is represented by stick model. Green and blue dotted lines represent H- bond.
| S. No. | Ligands | AutoDock v4.2.6 | AutoDock Vina | iGEMDOCK v2.1 |
|---|---|---|---|---|
| 1. | 24-methylene-cycloartanol | |||
| 2. | Alpha-spinasterol | |||
| 3. | Beta-sitosterol | |||
| 4. | Campesterol | |||
| 5. | Citrostadienol | |||
| 6. | Taraxerol | |||
| 7. | Hydroxychloroquine | |||
| 8. | Ivermectin |
Docking interactions of active components of N. sativa with N-terminal RNA binding domain (NRBD) of SARS-CoV-2 nucleocapsid protein (PDB ID: 6M3M) versus standard drugs hydroxychloroquine and ivermectin.
| AutoDock v4.2.6 | AutoDock Vina | iGEMDOCK v2.1 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S.No | Ligands | BE (kcal/mol) | Kd | Interacting amino acids | BE (kcal/mol) | Kd | Interacting amino acids | T.E. | VDW | HB | EI | Interacting amino acids |
| 1. | 24-methylene- cycloartanol | −8.29 | 842.64 nM | Ala126,Ala135,Asn49, Asp129, Asp64,Gly125, Gly130, IIe131,IIe132, Lys128,Phe67, Trp109, Trp133,Tyr124, | −9.8 | 76.87 nM | Gln161,Gln84,Glu137 | −96.16 | −91.43 | −4.72 | 0 | Arg69,Gln161,Gln84, |
| 2. | Alpha-spinasterol | −9.54 | 101.42 nM | Ala126,Ala135,Arg69,Asp64,Gln71, Gly130,Gly70,IIe131,IIe132, Leu65,Lys128,Lys66,Phe67,Pro68, Th136,Trp133,Tyr124Val134 | −9.6 | 101.42 nM | Ala107,Asp108,Asp164,Glu161, Glu167,Gly163His89, Leu162,Lys157,Lys92,Pro248,Thr301, Trp108,Trp93,Tyr264,Tyr264,Tyr273 | −91.33 | −84.04 | −7.29 | 0 | Asn109,Gln269,Glu161,Gly160, His89Leu162,Thr158,Val159 |
| 3. | Beta-sitosterol | −8.69 | 426.43 nM | Ala35,Arg69,Asp64,Gln71,Gly130, Gly70,IIe132,Leu65,Lys128, Lys66,Phe67,Pro68,Thr136, Trp109,Trp133,Tyr124,Val134 | −10.4 | 76.87 | Asn76,Gln161,Gln71,Gln84, Gly70Leu160,Leu162, Leu168,Leu57,Pro163,Pro81,Ser79, Thr136,Thr166,THr167,Tyr173 | −88.19 | −84.69 | −3.5 | 0 | Ala126,Arg69,Asn127,Asn155, Gly125,Gly70Ile131,Ile132, Lys128,Phe67,Pro68, Trp133,Tyr124 |
| 4. | Campesterol | −8.57 | 522.64 nM | Ala126,Ala135Arg69, Asn127Asp129, Gln71,Gly70,IIe131 ,Lys128,Lys66,Phe67,Pro68,Trp133, | −9.8 | 76.87 nM | Asn76,Gln161,Gln71,Gln84, Glu137,Gly165,Gly70,Leu160, Leu162,Leu168,Pro163Pro81,Ser79, Thr136,Thr166,THr167Thr77,Tyr173 | −93.83 | −90.33 | −3.5 | 0 | Gln161,Gln164,Gln84,Glu137, Gly165,Gly70,Leu162,Pro81,Ser79, Thr136,Thr166,Thr167 |
| 5. | Citrostadienol | −8.43 | 663.45 nM | Ala126,Arg69Asn127,Asn49, Asp129,Gly125,IIe131,IIe132, Lys128,Phe67,Pro152, Thr50,Trp133,Tyr124 | −8.9 | 259.96 | Ala156,Asn127Asn155,Asn76, Asn78,Asp145,Gln161, Ile158,Thr149,Thr50,Trp53,Val159 | −80.13 | −75.88 | −4.24 | 0 | Ala156,Ala157,Asn155Asp145, Glm161,Gly148,His146, Ile158,Thr149,Val159 |
| 6. | Taraxerol | −8.5 | 588.67 nM | Asn49,Asp129,Asp64, Gly130,IIe131IIe132, Leu65,Lys128Lys656Trp133,Tyr124 | −12.1 | 76.87 | Gln161,Gln71Gln84,Glu137, Gly165,Gly70,Ile75,Leu160, Leu162,Leu168,Pro163,Pro74Thr136, Thr166,Thr167,Thr173 | −96.11 | −93.61 | −2.5 | 0 | Gln161,Gln71,Gln84,Glu137, Gly165,Gly70,Ile75Leu160, Leu162,Leu168,Pro163,Pro74, Thr136,Thr166,Tyr173 |
| 7. | Hydroxychloroquine | −3.96 | 1.25 mM | Ala126,Arg69,Asn49,IIe131,IIe132, Lys66Phe67,Thr50,Trp133,Tyr124 | −6.7 | 588.67 | Arg150,Asn151,Asn155, Asn76Gly148,Ile147,Ile158, Ile75,The77,Thr149,Thr50,Trp53 | −78.61 | −75.11 | −3.5 | 0 | Ala156,Asn76,Asp145,Gln161, Gly148,His146,IIe147,IIe158, IIe75,Thr149,Thr77,Val159 |
| 8. | Ivermectin | −9.08 | 220.28 nM | Ala126,Arg89,Arg89,Asn127,Asn154, Asn155,Asn49,Asn76,Asn78,Asp64, Gly117,Gly125,IIe131, IIe132,Leu65Lys128, Lys66,Pro118,Thr50,Trp133,Trp53 | −9.8 | 76.87 | Ala157,Ala174,Ala56,Arg108, Arg150,His60,Pro152, Thr55,Thr58,Tyr110Tyr173,Val159 | −114.23 | −96.98 | −17.28 | 0 | Ala126,Ala51,Arg89,Asn127, Asn154,Asn155,Asn49,Asp129, Asp129,Asp64,Gly130,Ile131, Ile132,Leu65,Lys128,Lys66, Pro118,Thr50,Trp133, Tyr110,Tyr112 |
Docking interactions of active components of N. sativa with papain-like protease (PL-PRO) of SARS-CoV-2 (PDB ID: 6W9C) versus standard antiviral drugs hydroxychloroquine and ivermectin.
| AutoDock v4.2.6 | AutoDock Vina | iGEMDOCK v2.1 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. No. | Ligands | BE (kcal/mol) | Kd | Interacting amino acids | BE (kcal/mol) | Kd | Interacting amino acids | T.E. (kcal/m ol) | VDW | HB | EI | Interacting amino acids | |
| 1. | 24-methylene- cycloartanol | −8.32 | 800.77 nM | Asn109,Asn109,Cys270,Gln269,Gln269, Gln269,Glu161,Gly160Gly160, Gly161,His89,Leu162,Thr158,Val159 | −9.6 | 101.42 nM | Ala107,Asp108,Asp164,Glu161, Glu167,Gly163His89,Leu162, Lys157,Lys92,Pro248,Thr301, Trp108,Trp93,Tyr264Tyr264,Tyr273 | −84.63 | −78.99 | −5.64 | 0 | Asn109,Gln269,Gly160, Gly161,Leu162,Thr158Val159 | |
| 2. | Alpha-spinasterol | −9.41 | 126.53 | Asn109,Asn109,Asp108,Cys270,Cys270, Gln269,Gln269,Gln269,Glu161,Gly150, Gly160,His89Leu162,Leu162,Val159 | −9.0 | 220.28 nM | Asn109,Asp108,Cys270, Gln269,Glu161, Gly160,Gly160,His89Leu162,Val159 | −91.9152 | −86.94 | −4.97 | 0 | Asn109,Cys270Gln269, Glu161,Gly160, Leu162,Thr158,Val159 | |
| 3. | Beta-amyrin | −8.79 | 357.58 nM | Gln1005,Gln1010,IIe1013,Leu102, Leu763,The1006Thr100,Thr1009,Val1008 | −9.8 | 76.87 nM | Asn109Gln269,Glu161,Gly160, Leu162,Thr158,Val159 | −84.40 | −80.90 | −3.5 | 0 | Ala107,Asn267,Asp108,Asp164, Glu161,Glu167,Gly163,His89Leu162, Lys157,Lys92,Trp106,TYr264,Tyr268 | |
| 4. | Beta-sitosterol | −9.14 | 198.01 | Asn109Asn109,Asn109,Asp108Cys270, Cys270,Gln269,Gln269,Gln269,Glu161 ,Gly160,Gly160,His89,Leu162,Leu162,Val159 | −9.0 | 220.28 nM | Asn109,Gln269,Glu161, Gly160,Gly160, His89,Leu162,Thr158,Val159 | −98.20 | −92.93 | −5.27 | 0 | Asn109,Cys270Gln269,Glu161,Gly160, Gly160,His89,Leu162,Leu162,Thr158 | |
| 5. | Campesterol | −9.71 | 76.87 | Asn109,Asn109,Asn109,Asp108,Cys270Cys270, Gln269,Gln269,Gln269,Glu161,Gly160, Gly160,Leu162,Leu162,Leu162 | −9.2 | 155.9 nM | Asn109,Cys270Gln269,Glu161, Gly160Gly160,His89,Leu162, Thr158,Val159 | −96.65 | −96.65 | 0 | 0 | Asn109,Asp108,Gln269Glu161, Gly160,Gly160,His89,Leu162, Ser85,Thr158,Val159 | |
| 6. | Citrostadienol | −8.98 | 259.96 | Asn109,Asn109,Asn109,Asp108,Cys270, Gln269,Gln269,Glu161Glu161,Gly160, His89,Leu162,Leu162,Leu162, Thr158,Val159,Val159 | −9.5 | 101.42 nM | Ala107,Asn267,Asp108,Asp164, Glu161,Glu167,Gly266,His89,Leu162, Lys157,Lys92,Pro248Trp106, Trp93,Tyr264 | −91.70 | −86.45 | −5.25 | 0 | Ala86,Asn109Asp108,Glu161, Gly160,His89,Ser85,Thr158,Val159 | |
| 7. | Cycloartenol | −8.74 | 389.61 nM | Asn109,Asn109,Cys270,Gln269,Gln269, Gln269,Glu161,Glu161,Gly160,His89, Leu162,Leu162,Thr158,Val159 | −8.8 | 389.61 nM | Asn109,Asp108,Gln269, Glu161,Gly160,His89, Leu162,Thr158Val159,Val159 | −85.32 | −79.14 | −2.17 | 0 | Ala107,Asp108,Asp164,Glu161, Glu167,Gly163,His89,Leu162, Lys157,Lys92,Trp106,Tyr264 | |
| 8. | Cycloeucalenol | −9.65 | 84.23 | Asn109,Asn109,Asp108,Cys270,Gln269, Gln269,Gln269,Glu161,Glu161,Gly160Gly160, Gly160,Leu162,Leu162,Leu162,Val159 | −9.3 | 155.9 nM | Ala107,Asp108,Asp164, Glu161,Glu167,Gly163, His89,Leu162,Lys157, Lys92,Pro248Thr301, Trp106,Trp93,Tyr264,Tyr273 | −102.07 | −93.20 | −8.86 | 0 | Asn109,Asp108,Cys270, Gln269,Gln289Glu161, Gly160,Gly160,His89, Leu162,Val159 | |
| 9. | Taraxerol | −9.29 | 155.9 | Asn109,Asn109,Asn109, Cys270,Gln269Gln269, Gln269,Glu161,Gly160, Gly160,His89,Leu162, Leu162,Thr158,Val159,Val159 | −10.0 | 76.87 nM | Asn109,Cys270, Gln269,Glu161,Gly160, Gly160,Leu162,Thr158,Val159 | −100.31 | −90.34 | −9.96 | 0 | Asn109,Asp108,Gln269,Glu161, Gly160,Leu162,Thr158,Val159 | |
| 10. | Tirucallol | −8.78 | 368.93 nM | Asn109,Asn109,Asn109, Asp108,Cys270,Gln269, Gln269,Gln269,Glu160,Glu161,Glu161, Gly160,Leu162,Leu162,Thr158Val159 | −8.6 | 522.64 | Ala107,Asn267Asn267, Asp108,Asp164, Leu162,Leu289,Pro248, Trp106,Tyr264,Tyr268 | −84.35 | −81.07 | −3.27 | 0 | Asn109,Gln269Glu161,Gly160, Leu162,Thr158,Val159 | |
| 11. | Hydroxychloroquine | −5.93 | 44.86 | Asn109,Asn109,Asn109,Gln269,Gln269, Gln269,Glu161,Glu161,Gly160, Gly160,Leu162,Leu162 | −7.2 | 588.67 | Asn109,Gln269Glu161Gly160, Leu162 | −80.88 | −80.88 | 0 | 0 | Asn109,Cys270Gln269,Glu161, Gly160,Gly160,Leu162 | |
| 12. | Ivermectin | −4.98 | 224.79 | Asp108,Glu161,Glu161,Gly160,Gly160, His89Leu162,Thr158,Thr158, Thr158,Val159,Val159 | −9.3 | 155.9 nM | Ala153,Ala39,Arg82,Asn156, Asn88,Asp76,Cys155,His73,Ile44, Leu36,Lys92Ser78,Thr74, Tyr154,Tyr171 | −103.44 | −82.27 | −21.17 | 0 | Asp108,ASP108,Glu161, Gly160,Gly160,His89,Ser85, Thr158,Val159,Val159 | |
PASS analysis of major active components of N. sativa versus standard antiviral drugs hydroxychloroquine and ivermectin.
| Lipinski’s rule of 5 (Physicochemical Properties) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S.No. | Phytoconstituents | % Absorptiona | Topological Polar Surface Area (Å)2 | MW (<500) | c logPc (<5) | Heavy atom count | Hydrogen | Hydrogen Bond Acceptors (nON) | Number of | Lipinski’s |
| 1. | 24-methylene- | 102.02 | 20.23 | 440.76 | 8.03 | 32 | 1 | 1 | 5 | 1 |
| 2. | Alpha-spinasterol | 102.02 | 20.23 | 412.70 | 7.87 | 30 | 1 | 1 | 5 | 1 |
| 3. | Beta-amyrin | 102.02 | 20.23 | 426.73 | 8.02 | 31 | 1 | 1 | 0 | 1 |
| 4. | Beta-sitosterol | 102.02 | 20.23 | 414.72 | 8.62 | 30 | 1 | 1 | 6 | 1 |
| 5. | Campesterol | 102.02 | 20.23 | 400.69 | 8.30 | 29 | 1 | 1 | 5 | 1 |
| 6. | Citrostadienol | 102.02 | 20.23 | 426.73 | 8.15 | 31 | 1 | 1 | 5 | 1 |
| 7. | Cycloartenol | 102.02 | 20.23 | 426.73 | 8.21 | 31 | 1 | 1 | 4 | 1 |
| 8. | Cycloeucalenol | 102.02 | 20.23 | 426.73 | 7.62 | 31 | 1 | 1 | 5 | 1 |
| 9. | Taraxerol | 102.02 | 20.23 | 426.73 | 8.02 | 31 | 1 | 1 | 0 | 1 |
| 10. | Tirucallol | 102.02 | 20.23 | 426.73 | 8.48 | 31 | 1 | 1 | 4 | 1 |
| 11. | Hydroxychloroquine | 92.16 | 48.38 | 335.88 | 4.00 | 23 | 2 | 4 | 9 | 0 |
| 12. | Ivermectin | 50.31 | 170.09 | 875.11 | 4.58 | 62 | 3 | 14 | 8 | 3 |
Note:.
aPercentage Absorption was calculated as: % Absorption =109- [0.345xTopological Polar Surface Area].
bTopological polar surface area (defined as a sum of surfaces of polar atoms in a molecule).
cLogarithm of compound partition coefficient between n-octanol and water.
Best docking poses of active components of N. sativa with papain-like protease (PL-PRO) of SARS-CoV-2 (PDB ID: 6W9C) versus standard drugs hydroxychloroquine and ivermectin.
| S. No. | Ligands | AutoDock v4.2.6 | AutoDock Vina | iGEMDOCK v2.1 |
|---|---|---|---|---|
| 1. | 24-methylene-cycloartanol | |||
| 2. | Alpha-spinasterol | |||
| 3. | Beta-amyrin | |||
| 4. | Beta-sitosterol | |||
| 5. | Campesterol | |||
| 6. | Citrostadienol | |||
| 7. | Cycloartenol | |||
| 8. | Cycloeucalenol | |||
| 9. | Taraxerol | |||
| 10. | Tirucallol | |||
| 11. | Hydroxychloroquine | |||
| 12. | Ivermectin |
Druglikeness and toxicity calculations of N. sativa phytoconstituents versus standard drugs hydroxychloroquine and ivermectin.
| Druglikeness and Toxicity parameters | ||||||
|---|---|---|---|---|---|---|
| S. No. | Compounds Name | Druglikeness | Mutant | Tumurogenic | Reproductive effective | Irritant |
| 1. | 24-Methylene-Cycloartanol | −9.2281 | N | N | N | N |
| 2. | Alpha-Spinasterol | 1.2217 | N | L | N | N |
| 3. | Beta-Amyrin | −2.4858 | N | N | N | N |
| 4. | Beta-Sitosterol | −4.475 | N | N | N | N |
| 5. | Campesterol | −8.1908 | N | N | N | N |
| 6. | Citrostadienol | −5.602 | N | N | N | H |
| 7. | Cycloartenol | −4.1078 | N | N | N | H |
| 8. | Cycloeucalenol | −7.633 | N | N | N | N |
| 9. | Taraxerol | −2.422 | N | N | N | N |
| 10. | Tirucallol | −4.1331 | N | N | H | H |
| 11. | Hydroxychloroquine | 5.7266 | H | N | N | N |
| 12. | Ivermectin | 5.2314 | N | N | N | N |
N- No toxicity.
L- Low toxicity.
H- High toxicity.
Bioactivity scores of N. sativa phytoconstituents versus standard drugs hydroxychloroquine and ivermectin.
| Parameters of bioactivity score (BAS) | |||||||
|---|---|---|---|---|---|---|---|
| S. No. | Phytocomponents | GPCR Ligand | Ion Channel Modulator | Kinase Inhibitor | Nuclear Receptor Ligand | Protease Inhibitor | Enzyme Inhibitor |
| 1. | 24-Methylene-Cycloartanol | 0.14 | 0.11 | −0.37 | 0.90 | 0.06 | 0.60 |
| 2. | Alpha-Spinasterol | 0.18 | 0.05 | −0.30 | 0.68 | 0.06 | 0.53 |
| 3. | Beta-Amyrin | 0.22 | −0.05 | −0.31 | 0.67 | 0.11 | 0.56 |
| 4. | Beta-Sitosterol | 0.14 | 0.04 | −0.50 | 0.73 | 0.07 | 0.51 |
| 5. | Campesterol | 0.11 | 0.01 | −0.48 | 0.71 | 0.01 | 0.50 |
| 6. | Citrostadienol | 0.15 | 0.15 | −0.34 | 0.89 | 0.13 | 0.66 |
| 7. | Cycloartenol | 0.21 | 0.10 | −0.40 | 0.86 | 0.14 | 0.66 |
| 8. | Cycloeucalenol | 0.14 | 0.14 | −0.37 | 0.92 | 0.10 | 0.61 |
| 9. | Taraxerol | 0.21 | 0.02 | −0.20 | 0.54 | 0.00 | 0.49 |
| 10. | Tirucallol | 0.18 | −0.05 | −0.39 | 0.82 | 0.06 | 0.64 |
| 11. | Hydroxychloroquine | 0.35 | 0.30 | 0.44 | −0.12 | 0.12 | 0.15 |
| 12. | Ivermectin | −2.49 | −2.86 | −3.23 | −2.94 | −1.89 | −2.53 |
ADMET properties calculated for N. sativa phytoconstituents versus standard drugs hydroxychloroquine and ivermectin.
| S.No. | Phytocomponents | Lipophilicity | BBB permeant | P-gp substrate | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor | Log Kp (skin permeation) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. | 24-methylene-cycloartanol | 7.79 | No | No | No | No | No | No | No | −1.67 cm/s |
| 2. | Alpha-spinasterol (spinasterol) | 6.88 | No | No | No | No | No | No | No | −2.92 cm/s |
| 3. | Beta-amyrin | 7.18 | No | No | No | No | No | No | No | −2.41 cm/s |
| 4. | Beta-sitosterol | 7.19 | No | No | No | No | No | No | No | −2.20 cm/s |
| 5. | Campesterol | 6.90 | No | No | No | No | No | No | No | −2.50 cm/s |
| 6. | Citrostadienol (alpha1-sitosterol) | 7.26 | No | No | No | No | No | No | No | −2.49 cm/s |
| 7. | Cycloartenol | 7.51 | No | No | No | No | No | No | No | −1.96 cm/s |
| 8. | Cycloeucalenol | 7.45 | No | No | No | No | No | No | No | −1.87 cm/s |
| 9. | Taraxerol | 7.22 | No | No | No | No | No | No | No | −2.30 cm/s |
| 10. | Tirucallol | 7.42 | No | No | No | No | No | No | No | −2.58 cm/s |
| 11. | Hydroxychloroquine | 3.37 | Yes | No | Yes | No | No | Yes | No | −5.81 cm/s |
| 12. | Ivermectin | 4.35 | No | Yes | No | No | No | No | No | −7.14 cm/s |
Figure 1.PCA of leadlikeness of N. sativa phytoconstituents versus antiviral standard drugs hydroxychloroquine and ivermectin (A) Scatter plot (B) 3 D point plot.
Bravais-Pearson (linear correlation) coefficient of N. sativa phytoconstituents versus standard drugs hydroxychloroquine and ivermectin.
| Properties | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % Ab | 1 | −1 | −0.927 | 0.739 | −0.908 | −0.958 | −1 | −0.496 | −0.597 | 0.992 | −0.126 | 2.74E-04 | |
| TPSA | 2 | −1 | 0.928 | −0.737 | 0.909 | 0.957 | 1 | 0.494 | 0.599 | −0.992 | 0.123 | 2.76E-04 | |
| MW | 3 | −0.927 | 0.928 | −0.449 | 1 | 0.784 | 0.912 | 0.273 | 0.848 | −0.967 | −0.255 | −2.04E-06 | |
| logP | 4 | 0.739 | −0.737 | −0.449 | −0.407 | −0.894 | −0.764 | −0.646 | 0.0812 | 0.654 | −0.717 | 0.175 | |
| natoms | 5 | −0.908 | 0.909 | 1 | −0.407 | 0.752 | 0.891 | 0.241 | 0.873 | −0.953 | −0.302 | 0.00361 | |
| nOHNH | 6 | −0.958 | 0.957 | 0.784 | −0.894 | 0.752 | 0.969 | 0.609 | 0.343 | −0.915 | 0.399 | −0.0561 | |
| nON | 7 | −1 | 1 | 0.912 | −0.764 | 0.891 | 0.969 | 0.514 | 0.565 | −0.986 | 0.164 | −0.00802 | |
| Rb | 8 | −0.496 | 0.494 | 0.273 | −0.646 | 0.241 | 0.609 | 0.514 | 0.0808 | −0.429 | 0.556 | 0.0925 | |
| LV | 9 | −0.597 | 0.599 | 0.848 | 0.0812 | 0.873 | 0.343 | 0.565 | 0.0808 | −0.691 | −0.705 | 0.156 | |
| pc1 | 10 | 0.992 | −0.992 | −0.967 | 0.654 | −0.953 | −0.915 | −0.986 | −0.429 | −0.691 | −1.23E-10 | 1.14E-09 | |
| pc2 | 11 | −0.126 | 0.123 | −0.255 | −0.717 | −0.302 | 0.399 | 0.164 | 0.556 | −0.705 | −1.23E-10 | 3.36E-09 | |
| pc3 | 12 | 2.74E-04 | 2.76E-04 | −2.04E-06 | 0.175 | 0.00361 | 0.0561 | −0.00802 | 0.0925 | 0.156 | 1.14E-09 | 3.36E-09 |
Figure 2.Structural differences in 10 phytocomponents of N. sativa divided into three groups: Group (A) (b) alpha-spinasterol, (d) beta-sitosterol, (e) campesterol, (f) citrostadienol and (j) tirucallol; Group (B) (c) beta-amyrin and (i) taraxerol; Group (C) (a) 24-methylene-cycloartanol, (g) cycloartenol and (h) cycloeucalenol.
Figure 3.RMSD values of SARS-CoV-2 PL-PRO (PDB ID: 6W9C) complexed with cycloeucalenol were analyzed as a function of time at 300 K. Values were calculated with the use of Cα atoms. (A) Ligand-protein conformation (B) RMDS of receptor and ligand (C) RMSD histogram of receptor (D) RMSD histogram of ligand (E) Radiation of Gyration- Rg value (F) Fraction of native contacts analysis of SARS-CoV-2 PL-PRO (PDB ID: 6W9C) with cycloeucalenol, over a time frame of 4000ps (4 ns) (G) B-factor value (changing from blue to red with increase in value) (H) RMSF value of each residue and (I) B-factor analysis of defined complex.
Figure 4.RMSD values of NRBD of SARS-CoV-2 nucleocapsid protein (PDB ID: 6M3M) comlexed with alpha-spinasterol were analyzed as a function of time at 300 K. Values were calculated with the use of Cα atoms. (A) Ligand-protein conformation (B) RMDS of receptor and ligand (C) RMSD histogram of receptor (D) RMSD histogram of ligand (E) Radiation of Gyration- Rg value (F) Fraction of Native Contacts Analysis of SARS-CoV-2 NRBD of nucleocapsid protein (PDB ID: 6M3M) with alpha-spinasterol, over a time frame of 4000ps (4 ns) (G) B-factor value (changing from blue to red with increase in value) (H) RMSF value of each residue and (I) B-factor analysis of defined complex.